Article

From APOE Genetics to AI-Designed Drug Candidates: An Integrated Pipeline for Oral, Brain-Penetrant ACAT1 Inhibitors in Alzheimer’s Disease

2026-05-26

Abstract excerpt

For more than 55 million people living with dementia worldwide, no oral disease-modifying treatment is currently available. Alzheimer’s disease (AD) remains one of the most urgent unmet needs in neurology, with recent genetic evidence estimating that 72–93% of AD burden is attributable to common APOE allelic variation. Mechanistically, the APOE ε4 isoform impairs cholesterol transport in the brain, promoting chole...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: c1ef4797-9139-5eb3-8cb4-0e88796c48e2
DOI: 10.64898/2026.05.21.727002

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

From APOE Genetics to AI-Designed Drug Candidates: An Integrated Pipeline for Oral, Brain-Penetrant ACAT1 Inhibitors in Alzheimer’s DiseaseDOI 10.64898/2026.05.21.727002Read

The Alzheimer’s disease drug development landscapeSemantic proximity Read

Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transportersSemantic proximity Read

Computational Transformation of Chemical Biology for Precision Therapeutics: Facilitating In-Silico Study of Role of Cuproptosis in Early Detection of Alzheimer’s DiseaseSemantic proximity Read

Targeting CHI3L1 in Alzheimer’s Disease: Optimization of G721-0282 and Functional Evaluation in Astrocyte ModelsSemantic proximity Read

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).Semantic proximity Read

Pharmacogenetic Basis for Therapeutic Optimization in Alzheimer’s DiseaseSemantic proximity Read

Opportunities in pharmacogenomics for the treatment of Alzheimer’s diseaseSemantic proximity Read

Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program.Semantic proximity Read

African Natural Products for Multitarget-Based Treatment of Alzheimer’s Disease: An In Silico StudySemantic proximity Read

Repurposing Oncology Drugs for Alzheimer’s: Multi-Omic Convergence Targeting Cell-Cycle, Proteostasis, Immunometabolism, and SenescenceSemantic proximity Read

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity Read

A Novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer’s disease by dual inhibition of acetylcholinesterase and inflammationSemantic proximity Read